Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 1,617–1,624 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Eli Lilly and Company VTX3232 Obesity and cardiometabolic risk factors Phase 2 Data Released Oral Endocrinology
Eli Lilly and Company Tirzepatide - (SURMOUNT-4) Obesity or overweight with weight-related comorbidities Phase 3 Data Released Subcutaneous Endocrinology
Eli Lilly and Company Mirikizumab - (VIVID-2) Crohn's disease Phase 2 Data Released Intravenous Gastroenterology
Eli Lilly and Company Olomorasib KRAS G12C-mutant advanced solid tumors Phase 3 Ongoing Oral Oncology
Eli Lilly and Company Insulin efsitora alfa (efsitora) - (QWINT-3) Type 2 diabetes Phase 3 Data Released Subcutaneous injection Endocrinology
Eli Lilly and Company Insulin efsitora alfa (efsitora) - (QWINT-5) Type 2 diabetes Phase 3 Data Released Subcutaneous Endocrinology
Eli Lilly and Company Tirzepatide - (SURMOUNT-3) Obesity or overweight with weight-related comorbidities Phase 3 Data Released Subcutaneous Endocrinology
Elicio Therapeutics Inc. ANG-3070 Idiopathic Pulmonary Fibrosis Phase 2 Trial Discontinued oral Respiratory